Stay updated with breaking news from Ryan Sullivan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/GP47Q46RZFOAFCEAWZLKG35ANU.jpg)
An experimental mRNA vaccine developed by Moderna Inc combined with Merck & Co's blockbuster immunotherapy Keytruda cut the risk of death or recurrence of the most deadly skin cancer by 44% compared Keytruda alone, U.S. researchers reported at a medical meeting on Sunday.
The results add data details to partial findings released by the companies in December.
An experimental mRNA vaccine developed by Moderna Inc combined with Merck & Co's blockbuster immunotherapy Keytruda cut the risk of death or recurrence of the most deadly skin cancer by 44%
An mRNA vaccine from Moderna shows promise at preventing recurrences of melanoma skin cancer, which could mark a turnaround for cancer vaccines.
Merck's breakthrough immunotherapy Keytruda and Moderna's experimental mRNA vaccine decreased mortality or recurrence of the most deadly skin cancer by 44%.